A Phase 2 clinical trial testing Rivus Pharmaceuticals‘ experimental oral therapy HU6 in people with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of…

April 19 marks World Liver Day, a global effort to raise awareness about liver health and the growing burden of liver disease. This year’s…

The U.S. Food and Drug Administration (FDA) has granted fast-track designation to pevifoscorvir sodium, Aligos Therapeutics‘ oral therapy candidate for chronic hepatitis B, which…